Delivery accuracy of VMAT on two beam‐matched linacs provided by accelerated go live service

<jats:title>Abstract</jats:title><jats:sec><jats:title>Introduction</jats:title><jats:p>Dosimetric accuracy is critical when a patient treated with volumetric modulated arc therapy (VMAT) is transferred to another beam‐matched linac. To evaluate the performance of Accelerated Go Live (AGL) service, the measured beam characteristics and patient specific quality assurance (QA) results between two AGL‐matched linacs were compared.</jats:p></jats:sec><jats:sec><jats:title>Materials and Methods</jats:title><jats:p>Two VersaHD linacs were installed using the AGL service. After the installation, the beam data such as percentage depth dose (PDD), lateral profiles and output factors for all photon beams were measured. Relative doses were also measured as a function of the multi‐leaf collimator (MLC) leaf gap width. Subsequently, VMAT plans were created for prostate, pelvis, head and neck, liver, lung cancers and multiple brain metastases. Dose distributions and point doses were measured by multi‐dimensional detectors and ionization chambers for patient specific quality assurance, and comparisons were made between the two linacs.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Dose differences in PDDs were all within ± 1% except the entrance region, and the averaged gamma indices of the lateral profiles were within 0.3. The differences in doses as a function of the MLC leaf gap width between the two linacs were within ±0.5%. For all the plans, gamma passing rates were all higher than 95% with criteria of 2%/2 mm. The average and the SD of dose differences on the multi‐dimensional detector between both measurements was 0.06 ± 2.12%, and the average of point dose differences was −0.03 ± 0.33%.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>We have evaluated the AGL performance in the context of beam characteristics and patient specific QA. It was demonstrated that the AGL service provides an accurate VMAT treatment reproducibility for many tumor sites with gamma pass rates greater than 95% under criteria of 2%/2 mm.</jats:p></jats:sec>